U.S. Other Utilities Stock News

Markets are sending mixed signals right now, with softer inflation readings, uneven housing data and shifting global bond flows all pulling your portfolio in different directions. When headlines are noisy, low risk leaders with strong balance sheets can help you stay invested without leaning on guesswork about the next macro swing. Our Low-Risk Leaders screener focuses on companies that our model scores as having the lowest risk profiles, so you can concentrate on resilient businesses instead...

PNC Financial Services Group has delivered a strong 108.8% share price return over the past 3 years, and the current valuation picture now hinges on how that rally lines up with its intrinsic value estimate and broader checks. The 108.8% 3 year return suggests investors have already priced in a meaningful improvement in PNC Financial Services Group's earnings power. Recent earnings growth, a higher dividend, and ongoing technology investment can support higher valuations, while integration...

Kura Oncology previously announced that updated Phase 1a results from its FIT-001 trial of darlifarnib plus cabozantinib in advanced renal cell carcinoma were selected for an oral presentation at the 2026 Kidney Cancer Research Summit in Boston. The data highlight darlifarnib’s potential to enhance VEGFR-targeted therapies by inhibiting adaptive mTORC1 signaling, supporting Kura’s plan to position it as a precision combination backbone across multiple targeted therapy classes. We’ll now...

SELLAS Life Sciences Group stock has delivered a very large three year return while the broader valuation checks suggest the shares are expensive rather than a clear bargain. Over the past three years, SELLAS Life Sciences Group has returned about 7x, which puts extra attention on whether the current price already reflects much of the good news. Expectations for rapid revenue and earnings growth may support the current valuation, while the recently filed US$154.6m shelf registration...

Tariff headlines are no longer just background noise for investors. With trans-Pacific shipping demand cooling, freight rates under pressure and importers hesitating on orders, the latest round of U.S. trade uncertainty is starting to bite specific stocks tied to Asia to U.S. supply chains. For some companies, stalled shipments and a pulled-forward peak season could mean tougher volumes, uneven pricing power and more complex inventory choices. This article explains how that news risk affects...

Hingham Institution for Savings (HIFS) opened Q2 2026 with total revenue of US$42.4 million and basic EPS of US$11.59, supported by net income of US$25.4 million, setting a clear earnings tone for the quarter. The bank has seen quarterly revenue move from US$20.4 million and EPS of US$4.32 in Q2 2025 to US$34.5 million with EPS of US$9.49 in Q4 2025, before reaching the latest Q2 2026 levels, while trailing twelve month EPS stood at US$30.33 on revenue of US$119.5 million. With a reported net...

Gibraltar Industries (NasdaqGS:ROCK) has completed the sale of its Renewables business. The company is repositioning around core markets including residential, agtech, and infrastructure. The transaction reshapes Gibraltar Industries’ business mix and long term focus. The exit from renewables marks a clear refocus for Gibraltar Industries, which now centers its portfolio on residential products, controlled environment agriculture, and infrastructure solutions. For investors, this means the...

Sionna Therapeutics stock has delivered a sharp 195.2% return over the past year, yet its low value score and overvalued reading on the market multiples raise questions about how much upside is already reflected in the price. Over the past 1 year, Sionna Therapeutics has returned 195.2%, which puts the recent share price strength firmly in focus for anyone thinking about valuation. Expectations for the company’s drug pipeline can support a premium, but uncertainty around execution,...

Travel + Leisure stock has delivered a 96.3% return over the past three years, yet both its Discounted Cash Flow (DCF) intrinsic value estimate and earnings-based multiples still point to the shares trading at a discount to what the business may be worth. With the stock recently at US$73.27 and fresh acquisition news in play, the central question is whether the current price already reflects that upside. Over the last three years, Travel + Leisure has returned 96.3%, which puts extra focus...

Earlier this year, Revolve Group reported strong Q1 results, with revenue coming in 4.2% above analyst expectations and its buyer base expanding, which management linked to effective execution and market share gains. This combination of outperformance and customer growth suggests the company’s efforts in merchandising, marketing, and technology are translating into tangible operating momentum. Now we’ll explore how this revenue beat and expanding customer base may influence Revolve Group’s...

Regions Financial (RF) opened Q2 2026 with total revenue of US$1,839 million and basic EPS of US$0.64, supported by net income excluding extra items of US$549 million. The company has seen quarterly revenue move from US$1,779 million in Q2 2025 to US$1,839 million in Q2 2026, while basic EPS shifted from US$0.59 to US$0.64 over the same period, giving investors a clearer view of how the income line is tracking. With a trailing net profit margin of 29.7% and a net interest margin of 3.66%, the...

Pinnacle Financial Partners stock has delivered a 49.6% total return over the past three years, yet on current checks it screens as only a low-score value pick, while the Excess Returns intrinsic value estimate suggests the shares trade at a steep discount to fair value. That tension between a solid multi year return, an intrinsic value signal implying 42.1% upside and broader checks that lean cautious is what investors now have to weigh. A 49.6% return over three years points to a stock...

Sarepta Therapeutics stock is coming off a long period of weak share price performance, with a steep decline over the past three years sitting alongside a mixed valuation profile and fresh regulatory progress that could influence how investors think about what the shares are worth today. Over the past three years, Sarepta Therapeutics has fallen 83.7%, which places the current valuation in the context of a prolonged drawdown rather than a recent rally. The FDA’s acceptance of supplemental...

Tech stocks, including DoubleVerify Holdings (DV), came under pressure after an oil shock and a renewed U.S. naval blockade on Iran raised concerns about prolonged higher interest rates and tighter funding conditions. See our latest analysis for DoubleVerify Holdings. The latest pullback in DoubleVerify Holdings reflects the broader risk-off mood in tech, with the stock down 3.22% on a 1 day share price return basis and 2.14% over 7 days. Its 30 day share price return of 10.55% and year to...

Universal Insurance Holdings has delivered a very strong 265.7% total return over the past 5 years, yet its current valuation checks and intrinsic value estimate both indicate the stock still trades at a discount to what the business may be worth. With the share price at US$38.91, the Excess Returns model and earnings multiples are broadly aligned in suggesting the market could be pricing Universal Insurance Holdings below its intrinsic value. Over 5 years, the stock is up 265.7%, which puts...

The new US tariffs on Brazilian imports are shaking up expectations for US industrial and manufacturing stocks, from steel and paper to agricultural and electrical machinery. With certain Brazilian goods facing total tariffs of up to 37.5% and others exempt, some US companies could see fresh tailwinds while others face new cost and supply questions. This article focuses on US Domestic Industrial & Manufacturing Stocks that are exposed to these trade shifts and may be influenced by changing...

Ames National (ATLO) has posted Q2 2026 results with total revenue of US$18.9 million and net income of US$5.9 million, translating to basic EPS of US$0.67 and a trailing twelve month EPS of US$2.59. Over recent quarters the company has seen revenue move from US$16.0 million in Q2 2025 to US$18.9 million in Q2 2026, while quarterly EPS shifted from US$0.51 to US$0.67 and trailing net income reached US$23.0 million. This gives investors a clearer picture of earnings momentum backed by a...

Fifth Third Bancorp (FITB) opened Q2 2026 with total revenue of US$3.1 billion and basic EPS of US$0.84, putting fresh numbers on the table for investors tracking its profit engine. The company reported quarterly revenue of US$2.1 billion in Q2 2025 and US$3.1 billion in Q2 2026, while basic EPS over the same quarters moved from US$0.88 to US$0.84, setting the scene for a set of results where profitability and margins are firmly in focus. See our full analysis for Fifth Third Bancorp. With...

Lindsay Corporation recently announced that Senior Vice President and Chief Financial Officer Sam Hinrichsen will resign effective August 31, 2026, for personal reasons, while continuing to provide transition services through year-end under a written agreement. The company also increased its regular quarterly dividend to US$0.38 per share, a move that can underscore management’s confidence in ongoing cash generation and capital-return priorities. Next, we’ll assess how the dividend increase,...

Establishment Labs Holdings has delivered a strong 122.7% return over the past year, yet its valuation checks lean expensive, with the stock flagged as overvalued on market multiples and scoring poorly on broader value tests. Over the last 1 year, Establishment Labs Holdings has returned 122.7%, which puts extra attention on whether the current share price already reflects much of the good news. Expectations for continued business expansion and cash generation can support a premium, but any...

With inflation trends, interest-rate expectations, and energy prices all pulling markets in different directions, many investors are looking for stocks where analysts still see clear earnings growth potential alongside balance sheets that appear reasonably sound. That is exactly what the Healthy high growth potential screener targets, focusing on companies where analysts expect solid earnings expansion over the next 3 years while also passing basic financial health checks. In this article,...

Progressive stock has pulled back recently after profitability concerns, yet over the last five years it has still delivered strong gains, leaving investors asking whether the current valuation now fairly reflects both that track record and the rising loss costs in its core insurance lines. A roughly 145% return over five years shows Progressive has created substantial shareholder value, which can make today’s price feel less like a clear bargain and more like a test of staying...

Smithfield Foods (SFD) stock has been drawing attention after recent price moves, including a 0.6% gain over the past day and a 4.5% rise over the past week, prompting closer scrutiny from investors. See our latest analysis for Smithfield Foods. At a share price of $25.77, Smithfield Foods shows short term momentum with a 7 day share price return of 4.46%. However, the 90 day share price return is down 11.14%, while the 1 year total shareholder return of 14.24% suggests recent gains are still...

Regency Centers stock has delivered a 55.4% return over the past 5 years, and both the Discounted Cash Flow (DCF) intrinsic value estimate and the market multiples currently point to the shares trading below what those models suggest, yet the broader valuation checks send a more mixed signal. With the share price recently closing at US$82.68, the question is how much room is left before that apparent discount is fully reflected. Regency Centers has returned 55.4% over 5 years, which puts...